AI Article Synopsis
- Endocrine therapy is standard for ER-positive breast cancer patients, but not all benefit, highlighting the complexity introduced by ERβ and its isoforms.
- Two retrospective studies had opposite findings on the prognostic value of ERβ isoforms in tamoxifen-treated patients, motivating this research.
- This study found that ERβ2 expression is linked to poorer disease-free and overall survival, particularly for patients treated with tamoxifen, suggesting ERβ2 as a potential prognostic marker and therapeutic target.
Article Abstract
Endocrine therapy is provided to all patients with estrogen receptor (ER)-positive breast cancer, but only a subset of them derives clinical benefit. The discovery of ERβ and its five isoforms added another layer of complexity in the regulation of estrogen activity in breast cancer cells. Two large retrospective studies showed conflicting results with regard to the prognostic value of the different ERβ isoforms in patients treated with tamoxifen in an adjuvant setting. This study tested the hypothesis that ERβ1 and, or ERβ2 are correlated with clinical outcome. We identified patients with breast cancer who had undergone surgery at Bucheon St. Mary's Hospital, the Catholic University of Korea, between January 2004 and March 2006. We evaluated 101 consecutive cases for ERβ1 and ERβ2 expression using immunohistochemical staining and obtained other clinicopathology by reviewing medical records. ERβ1 was expressed in 81.2% (79 of 97) and ERβ2 was expressed in 50.5% (51 of 101) of primary breast cancer tissues. Disease-free survival (DFS) and overall survival (OS) of patients with cancers expressing ERβ2 was significantly worse. Moreover, in subgroup analysis according to the tamoxifen treatment, ERβ2 expression was significantly associated with shorter DFS of tamoxifen-treated patients. This study indicates that breast cancer with ERβ2 expression was associated with worse DFS and OS, especially in tamoxifen treated patients. Our results suggest a role for ERβ2 as an independent prognostic marker and might serve as a new therapeutic target.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijsu.2014.10.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Controlled Inflammation Drives Neutrophil-Mediated Precision Drug Delivery in Heterogeneous Tumors.
Adv Sci (Weinh)
January 2025
Department of Radiology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, P. R. China.
Tumor heterogeneity remains a formidable obstacle in targeted cancer therapy, often leading to suboptimal treatment outcomes. This study presents an innovative approach that harnesses controlled inflammation to guide neutrophil-mediated drug delivery, effectively overcoming the limitations imposed by tumor heterogeneity. By inducing localized inflammation within tumors using lipopolysaccharide, it significantly amplify the recruitment of drug-laden neutrophils to tumor sites, irrespective of specific tumor markers.
View Article and Find Full Text PDFTransforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
Int J Clin Oncol
January 2025
Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.
View Article and Find Full Text PDFThe prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.
Breast Cancer Res Treat
January 2025
Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Purpose: To evaluate the prognostic significance of changes in pre- and post-neoadjuvant chemotherapy (NACT) Ki67 in patients with primary invasive triple-negative breast cancer (TNBC).
Methods: Population-based registry data were retrieved for patients diagnosed with TNBC between 2007 and 2021 (n = 9262). Multivariable Cox regression analysis was performed for disease-specific survival (DSS) and overall survival (OS) adjusted for age and residual disease in the breast and nodes (RDBN).
Elevated MRPS23 expression facilitates aggressive phenotypes in breast cancer cells.
Cell Mol Biol (Noisy-le-grand)
January 2025
Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Mitochondrial ribosomal protein S23 (MRPS23), encoded by a nuclear gene, is a well-known driver of proliferation in cancer. It participates in mitochondrial protein translation, and its expression association has been explored in many types of cancer. However, MRPS23 expression associations are rarely reported in breast cancer (BC).
View Article and Find Full Text PDFEvaluation of the antiproliferative effect of histone deacetylase inhibitor (HDACi) CI-994 and Liposomal Cisplatin LipoPlatin on MCF-7 and MDA-MB-231 cells as monotherapy and combined therapy.
Cell Mol Biol (Noisy-le-grand)
January 2025
Istanbul University, Faculty of Science, Department of Biology, Istanbul, Türkiye.
In this study, the effects of histone deacetylase inhibitor CI-994 and nanotechnological drug liposomal cisplatin LipoPlatin on Luminal A breast cancer and triple-negative breast cancer were explored using agents alone and in combination. MCF-7 and MDA-MB-231 cell lines were used. Cell viability, and cell index values obtained from xCELLigence System, MI, BrdU LI and AI were evaluated in experiments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!